Sign inJoin waitlistJoin the waitlist

Mohamed Sorror

Professor, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
1996–1999
MD, Assiut University
1993–1996
MD, Assiut University
Doctor of Medicine
1989–1993

Research

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
Blood · 2005 · First of 7 authors · 2,577 citations
Reduced mortality after allogeneic hematopoietic-cell transplantation
New England Journal of Medicine · 2010 · 1,235 citations
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation
Journal of Clinical Oncology · 2011 · 529 citations

Brenda Sandmaier
66 papers
Rainer Storb
64 papers
David Maloney
42 papers
Frederick Appelbaum
32 papers
Joachim Deeg
26 papers
MM
Michael Maris
24 papers
Richard Maziarz
24 papers
BS
Bipin Savani
23 papers
Paul Martin
20 papers
TC
Thomas Chauncey
19 papers
Michael Pulsipher
16 papers
Bart Scott
15 papers

Grants

Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality
National Cancer Institute · R01
Contact PI · $4.1M · Fred Hutchinson Cancer Center
2018–2026
Impact of Comorbidities on Outcomes of Allogeneic Transplantation
National Heart, Lung, and Blood Institute · R00
Contact PI · $735K · Fred Hutchinson Cancer Research Center
2011–2016
Impact of Comorbidities on Outcomes of Allogeneic Transplantation
National Heart, Lung, and Blood Institute · K99
Contact PI · $178.3K · Fred Hutchinson Cancer Research Center
2006–2010

Clinical trials

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
Principal investigator · Terminated · Phase 2, Phase 3
Fred Hutchinson Cancer Center
2019–2025
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
Principal investigator · Completed
Center for International Blood and Marrow Transplant Research
2019–2023
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Principal investigator · Withdrawn · Phase 2
Fred Hutchinson Cancer Center
2016
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
Principal investigator · Completed
Fred Hutchinson Cancer Center
2013–2018